Overdrive Update: Guselkumab for Treating Active Psoriatic Arthritis Part 2

Mar 14, 04:21 PM

On this month’s episode, I spoke with Soumya D. Chakravarty, MD, PhD, to discuss the growing body of clinical evidence evaluating joint efficacy, safety and patient-reported outcomes in patients with psoriatic arthritis receiving guselkumab.

Time Stamps:
0:50: Can you tell me more about guselkumab and how it is used to treat patients with psoriatic arthritis? 
3:32: What were the study designs and methods used in developing the DISCOVER-1 and DISCOVER-2 trials?
5:43: What were the primary (and any secondary) endpoints evaluated in these trials? 
7:00: What were the results regarding efficacy, safety, and patient-reported outcomes that were presented at the ACR? 
9:23: What does this clinical research mean for both rheumatologists and their patients? 
12:07: Is there anything else you'd like our audience to know about guselkumab or Janssen before we wrap up?